No, RLS is NOT a facial or connective tissue disorder
Restless legs syndrome (RLS) is a neurological sensorimotor disorder, not a facial or connective tissue condition. The disorder primarily affects the legs and is characterized by an urge to move associated with uncomfortable sensations, worsening at rest and in the evening 1, 2.
What RLS Actually Is
RLS is fundamentally a somatosensory network disorder involving:
- Dysfunction in dopaminergic pathways
- Brain iron deficiency
- Altered adenosine and glutamatergic systems
- Nociceptive system abnormalities 2, 3
The pathophysiology centers on neurological mechanisms, not structural tissue problems. Various lesions from peripheral neuropathies to spinal cord alterations to brain metabolism changes can contribute 3.
Why the Confusion About Facial Involvement?
While RLS can rarely extend to the face, this does not make it a facial disorder:
- Symptoms most frequently affect the legs, followed by arms 4
- Facial extension is extremely uncommon and represents either disease progression or augmentation (iatrogenic worsening from dopaminergic treatment) 4
- Case reports describe "restless face" as a variant presentation, not the primary disorder 5
- These facial symptoms still respond to the same dopaminergic and gabapentinoid treatments used for leg symptoms 4, 5
Clinical Implications
The 2025 AASM guidelines focus treatment on:
- First-line: Gabapentinoids (gabapentin enacarbil, gabapentin, pregabalin) - strong recommendations 6
- Iron supplementation: IV ferric carboxymaltose for appropriate iron status - strong recommendation 6
- Dopamine agonists: Now relegated to conditional "suggest against standard use" due to augmentation risk 6
None of these treatments target connective tissue or facial structures—they all address neurological pathways.
Common Pitfall
Do not misdiagnose RLS as a musculoskeletal or connective tissue disorder simply because patients describe leg discomfort. The key distinguishing features are: